Quantinno Capital Management LP Acquires 8,172 Shares of Bruker Co. (NASDAQ:BRKR)

Quantinno Capital Management LP boosted its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 210.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,057 shares of the medical research company's stock after buying an additional 8,172 shares during the quarter. Quantinno Capital Management LP's holdings in Bruker were worth $707,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. raised its position in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after buying an additional 248 shares during the last quarter. Quadrant Capital Group LLC raised its position in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after buying an additional 196 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Bruker by 41.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after purchasing an additional 390 shares during the last quarter. Parvin Asset Management LLC purchased a new stake in shares of Bruker during the 4th quarter valued at $112,000. Finally, GeoWealth Management LLC increased its position in shares of Bruker by 1,093.9% during the 4th quarter. GeoWealth Management LLC now owns 2,137 shares of the medical research company's stock valued at $125,000 after purchasing an additional 1,958 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Performance

BRKR traded up $1.65 during trading hours on Tuesday, hitting $37.15. The stock had a trading volume of 1,589,020 shares, compared to its average volume of 1,628,028. The company's fifty day simple moving average is $39.19 and its 200 day simple moving average is $49.45. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $77.61. The stock has a market cap of $5.63 billion, a PE ratio of 48.88, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The business had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. During the same quarter last year, the company earned $0.53 EPS. The firm's revenue was up 11.0% compared to the same quarter last year. Equities analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be paid a $0.05 dividend. The ex-dividend date is Monday, June 16th. This represents a $0.20 annualized dividend and a yield of 0.54%. Bruker's dividend payout ratio is currently 38.46%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus decreased their target price on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research report on Monday, February 24th. The Goldman Sachs Group decreased their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Citigroup lowered Bruker from a "strong-buy" rating to a "hold" rating and decreased their target price for the company from $50.00 to $40.00 in a research report on Thursday, May 22nd. Finally, Barclays decreased their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $59.10.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.